Metabolic syndrome and alanine aminotransferase: a global perspective from the NAVIGATOR screening population

Bethel, M A; Deedwania, P; Levitt, N S; Schmitz, O; Huntsman-Labed, A; Califf, R M; Haffner, S M; Diem, P (2009). Metabolic syndrome and alanine aminotransferase: a global perspective from the NAVIGATOR screening population. Diabetic medicine, 26(12), pp. 1204-11. Chichester: Wiley 10.1111/j.1464-5491.2009.02864.x

Full text not available from this repository. (Request a copy)

Non-alcoholic fatty liver disease (NAFLD) is associated with features of the metabolic syndrome (MetS) and may be an expression of the syndrome within the liver. Using screening data from the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) study (n = 42 149), we examined whether alanine aminotransferase (ALT), a biomarker for NAFLD, clustered with features of MetS and whether the clusters differed across global geographic regions.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Endocrinology, Diabetology and Clinical Nutrition

UniBE Contributor:

Diem, Peter

ISSN:

0742-3071

Publisher:

Wiley

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 15:14

Last Modified:

06 Dec 2013 13:59

Publisher DOI:

10.1111/j.1464-5491.2009.02864.x

PubMed ID:

20002471

Web of Science ID:

000272161900004

URI:

https://boris.unibe.ch/id/eprint/32470 (FactScience: 197679)

Actions (login required)

Edit item Edit item
Provide Feedback